Prelude Therapeutics (PRLD) Change in Accured Expenses (2019 - 2026)

Prelude Therapeutics has reported Change in Accured Expenses for 8 years, with the latest figure at -$6.6 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 66.38% year-over-year to -$6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.6 million (down 712.88% YoY) and the FY2025 annual result came in at -$3.0 million, down 268.81% from the prior year.
• Change in Accured Expenses eased to -$6.6 million in Q1 2026 per PRLD's latest filing, from -$515000.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $4.4 million in Q4 2023 and troughed at -$6.6 million in Q1 2026.
• A 5-year average of -$60882.4 and a median of $896000.0 in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses soared 583.8% in 2022, then tumbled 389.06% in 2023.
• Over 5 years, Change in Accured Expenses stood at $3.2 million in 2022, then jumped by 38.56% to $4.4 million in 2023, then tumbled by 64.35% to $1.6 million in 2024, then slumped by 132.87% to -$515000.0 in 2025, then plunged by 1181.94% to -$6.6 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$6.6 million, -$515000.0, and -$367000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.